Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

The mutation in the HEXA genes causes GM2 Gangliosidosis, often known as Tay-Sachs disease, which leads in muscle atrophy. Because there is no known cure for this disease, treatment is usually symptom-specific. Exaggerated reactions to loud noises, seizures, loss of movement, vision, and hearing, mucus collection in the lungs, and other symptoms are some of the signs and symptoms. Hexosaminidase disease is another name for Tay-Sachs disease. A deficiency is a rare inherited neurological illness caused by a lack of the enzyme hexosaminidase A, which causes G2 ganglioside buildup. These materials build up in the brain, affecting nerve cell activity and causing other neurological issues.

Impact of Covid-19 pandemic on market

The onset of the COVID19 outbreak demonstrates a significant global health threat. The market has been harmed as a result of regulatory authorities issuing guidelines and rules to treat patients with acute emergency in order to prevent the spread of the COVID-19 virus. Global GM2 Gangliosidosis or Tay-Sachs Disease Treatment Market will increase at a moderate rate following the Covid-19 issue, according to this analysis. Over the projection period, market size will moderately increase due to new discoveries in Tay-Sachs Disease Treatment and COVID19's impact.

Growth in business operations by emerging and small sized players

The increasing prevalence of genetic illness, particularly among neonates, is responsible for the market's growth. Furthermore, rising investment in R&D efforts to create new treatment approaches to cure the genetic disorder, as well as the introduction of new and improved pharmaceuticals to treat symptoms and consequences associated with the disease, are expected to drive market expansion. High demand for disease-specific new treatments can potentially boost the market. The introduction of medications to treat GM2 Gangliosidosis-related complications is boosting market growth.

On region the global GM2 Gangliosidosis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Over the forecast period, the market in North America is expected to increase significantly. Furthermore, the advanced healthcare system in the region, as well as expanding R&D activities, are expected to drive market expansion. Due to the significant Jewish population in Israel and other nearby countries, the Middle East and Africa market is expected to increase moderately throughout the forecast period.                                                                                                           

The global GM2 Gangliosidosis market is segmented based on type, therapeutic, drugs, and region.

On the basis of Type, the global GM2 Gangliosidosis market is segmented into Infantile, Juvenile and Adults. Based on Therapeutic, the target market is segmented into Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy. On the basis of Drugs, the target market is segmented into Anticonvulsant, Antipsychotic medication and Others.

Regional Insights:

On region the global GM2 Gangliosidosis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Over the forecast period, the market in North America is expected to increase significantly. Furthermore, the advanced healthcare system in the region, as well as expanding R&D activities, are expected to drive market expansion. Due to the significant Jewish population in Israel and other nearby countries, the Middle East and Africa market is expected to increase moderately throughout the forecast period.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global GM2 Gangliosidosis market report based on type, therapeutic, drugs, and region.

Global GM2 Gangliosidosis Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

Company Profile:

• Pfizer, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Eli Lilly and Company
• Bristol-Myers Squibb Company
• AstraZeneca
• Novartis AG
• Recursion Pharmaceuticals, Inc.
• IntraBio Inc.
• Johnson & Johnson Services, Inc.,
• Axovant Sciences, Inc.

 “*” marked represents similar segmentation in other categories in the respective section

The key players operating in the global GM2 Gangliosidosis market includes Pfizer, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Novartis AG, and others. Recursion Pharmaceuticals, Inc., IntraBio Inc., Johnson & Johnson Services, Inc., and  Axovant Sciences, Inc. To expand their footprints in this market, key companies have employed various methods such as new product releases, expansions, agreements, joint ventures, partnerships, acquisitions, and others.

• Pfizer, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Eli Lilly and Company
• Bristol-Myers Squibb Company
• AstraZeneca
• Novartis AG
• Recursion Pharmaceuticals, Inc.
• IntraBio Inc.
• Johnson & Johnson Services, Inc.,
• Axovant Sciences, Inc.

 “*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for GM2 Gangliosidosis Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Type
     • Market Snippet, By Therapeutic
     • Market Snippet, By Drugs
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Global GM2 Gangliosidosis Market, By Type , 2020 – 2030, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Infantile
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Juvenile
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Others
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
6. Global GM2 Gangliosidosis Market, By Therapeutic, 2020 – 2030, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Enzymatic augmentation
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Bone marrow transplantation
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Enzyme enhancement
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Substrate reduction therapy
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
7. Global GM2 Gangliosidosis Market, By Drugs, 2020 – 2030, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Anticonvulsant
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Antipsychotic medication
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Others
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030

8. Global GM2 Gangliosidosis Market, By Region, 2020 – 2030, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Therapeutic, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Drugs, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Therapeutic, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Drugs, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Therapeutic, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Drugs, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific
   • Latin America
     • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Therapeutic, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Drugs, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • Brazil
       • Mexico
       • Rest of Latin America
   • Middle East & Africa
     • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Therapeutic, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Drugs, 2020 – 2030
     • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
       • GCC
       • Israel
       • South Africa
       • Rest of Middle East
9. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
10. Company Profiles

• Pfizer, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• AstraZeneca
• Novartis AG
• Recursion Pharmaceuticals, Inc.
• IntraBio Inc.
• Johnson & Johnson Services, Inc.,
• Axovant Sciences, Inc.

The Last Word

• • Future Impact
  • About Us
  • Contact